In short

Tirzepatide has faced the same regulatory sequence as semaglutide: compounding expanded under shortage conditions and the basis narrowed when shortage status.

By Alsen Walker · Updated September 20, 2026

By Alsen Walker · Editorially reviewed on 25 August 2026 · Not medically reviewed by a clinician

Tirzepatide has faced the same regulatory sequence as semaglutide: compounding expanded under shortage conditions and the basis narrowed when shortage status changed. The current position must be checked directly rather than assumed, because it has moved and may move again.

Verify the current status with FDA before relying on anything written about this, including this page. Sellers have a commercial interest in the previous position, and articles lag. This is the fastest-moving regulatory area in this subject.

For the wider picture on compounded products and how to check a supplier, see Compounded GLP-1s: What They Are and How to Check a Supplier.

The same mechanism as semaglutide

Compounding copies of an approved drug is restricted. A shortage designation eases that restriction. When the shortage resolves, the basis narrows again, usually with a transition period rather than an immediate stop.

Tirzepatide followed that path. The details of timing and transition differ from semaglutide, which is one reason to check the specific product rather than generalising.

What differs from semaglutide in practice

Concentrations and presentations differ, so dosing instructions written for one are not transferable to the other. This should be obvious and is a documented source of error.

Salt form variants have appeared here as they did with semaglutide, and the same concerns apply: a different substance from the approved active ingredient, with unestablished equivalence.

Personalised or combination formulations have been marketed as falling outside copy restrictions. Whether that holds is contested and has attracted regulatory attention.

What to ask

On what basis is compounded tirzepatide still being supplied to you.

Which pharmacy or outsourcing facility prepares it, by name.

Exactly which substance and concentration, in writing.

What happens to your supply if the position changes again.

Whether they will help you transition to an approved product, and what that costs.

If your supply stops

This has happened to people abruptly, sometimes with little notice.

Transitioning to an approved product is not a dose-for-dose swap, since concentrations and presentations differ. That is a prescriber decision.

An approved product needs prior authorization, which takes time. Start that conversation before you are out rather than after.

The wider point

Compounded supply has always been conditional on a regulatory position rather than on a stable legal footing.

If you are relying on it as an ongoing treatment for a chronic condition, that conditionality is worth factoring into your planning rather than discovering when it changes.

The same sequence played out with semaglutide, covered in the FDA shortage list and what changed. If you are moving to an approved product, there is no simple dose conversion and your prescriber decides where to start.

Frequently asked questions

Is compounded tirzepatide still legal?
Depends on current status and guidance. Verify with FDA directly.

My provider is still selling it. Does that mean it is permitted?
Not necessarily, and they have a commercial interest. Verify independently.

Can I switch to the approved product at the same dose?
Not a straight swap. Concentrations differ and it is a prescriber decision.

What about personalised formulations?
Contested. Variation without clinical rationale has drawn regulatory attention.

Will insurance cover the compounded version?
No. Standard plans do not cover compounded GLP-1s.

What if I have supply left?
Speak to a prescriber rather than continuing without knowing what you have.

More in Compounded & Sourcing

All Compounded & Sourcing guides →

Alsen Walker is a health writer and researcher at GLP1Hub with five years of experience researching and writing health and medical content. He works in a medical-field role alongside his undergraduate studies. At GLP1Hub he researches GLP-1 weight loss programs, pricing and insurance rules, and checks claims against FDA prescribing information, published clinical trials and official government sources. Alsen is not a physician, and his articles are general information, not medical advice.